| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8124643 | SIGA TECHNOLOGIES | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun, 2024
(8 months from now) | |
| US9339466 | SIGA TECHNOLOGIES | Polymorphic forms of ST-246 and methods of preparation |
Mar, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8802714 | SIGA TECHNOLOGIES | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun, 2024
(8 months from now) | |
| US8530509 | SIGA TECHNOLOGIES | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun, 2024
(8 months from now) | |
| US8039504 | SIGA TECHNOLOGIES | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jul, 2027
(3 years from now) | |
| US9907859 | SIGA TECHNOLOGIES | ST-246 liquid formulations and methods |
Aug, 2031
(7 years from now) | |
| US9233097 | SIGA TECHNOLOGIES | ST-246 liquid formulations |
Aug, 2031
(7 years from now) | |
| US10576165 | SIGA TECHNOLOGIES | ST-246 liquid formulations and methods |
Aug, 2031
(7 years from now) | |
| US7737168 | SIGA TECHNOLOGIES | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Sep, 2031
(7 years from now) | |
Tpoxx is owned by Siga Technologies.
Tpoxx contains Tecovirimat.
Tpoxx has a total of 9 drug patents out of which 0 drug patents have expired.
Tpoxx was authorised for market use on 18 May, 2022.
Tpoxx is available in solution;intravenous dosage forms.
Tpoxx can be used as tpoxx is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 3 kg, treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg.
Drug patent challenges can be filed against Tpoxx from 2022-07-13.
The generics of Tpoxx are possible to be released after 04 September, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 13, 2023 |
Drugs and Companies using TECOVIRIMAT ingredient
NCE-1 date: 2022-07-13
Market Authorisation Date: 18 May, 2022
Treatment: Treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg; Tpoxx is indicated for the treatment of human smallpox disease in adults and pedia...
Dosage: SOLUTION;INTRAVENOUS
TPOXX family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic